NIH-funded research NIH-funded research

Antiplatelet therapy after spontaneous SCAD

Official title: 2/2- Antiplatelet Therapy in Spontaneous Coronary Artery Dissection (APT-SCAD)

Funded at Icahn School of Medicine at Mount Sinai · NIH-11451826 · Data updated 2026-11-12

This study tests whether a longer, more intensive antiplatelet plan helps people who had SCAD and are treated without surgery.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionIcahn School of Medicine at Mount Sinai
NIH-funded
Lab location1 site (New York, United States)
Project startSeptember 5, 2026
Project endJuly 31, 2027
Funding year2026
Award (this year)$803,661
NIH project number1UG3HL181193-01A1
Project IDNIH-11451826 on NIH RePORTER

Who could benefit from this research

Could help

Adults with conservatively managed SCAD presenting with ACS who are candidates for antiplatelet therapy.

Less likely to help

Patients not eligible for this treatment approach or with contraindications to antiplatelet drugs may not benefit.

What this research studies

Spontaneous coronary artery dissection (SCAD) can cause heart problems, especially in younger women. The trial compares an intensive 12-month antiplatelet plan (DAPT for 3 months, then clopidogrel for 9 months) with a shorter 3-month aspirin-only plan in patients whose SCAD was managed without intervention. Researchers will monitor outcomes like recurrent events and bleeding to see which approach is safer and more effective. The goal is to guide doctors on the best medicines to prevent future problems after SCAD. Participation would involve follow-up visits and medication adherence over a year.

Why it matters

Potential benefit: If successful, patients could receive a clearer, safer treatment plan that reduces risk of future heart events after SCAD.

How similar studies have gone: Few randomized trials exist in SCAD; this study is designed to provide high-quality evidence in this area.

Where this research is happening

  • Icahn School of Medicine at Mount Sinai
    New York, United States
    Active

Researchers

  • Principal investigator: Mehran, Roxana — Icahn School of Medicine at Mount Sinai
  • Study coordinator: Mehran, Roxana

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.